We have compared murine cytomegalovirus (MCMV) antibody determination by enzyme-linked immunosorbent assay (ELISA) and indirect immunofluorescence assay. A comparison of antibody detection with 146 serum samples at a 1:20 dilution showed 100% agreement (60 negatives and 86 positives) between the assays. There was close agreement of endpoint determinations of sera by both methods. After experimental MCMV infection, antibody to MCMV was detected by both assays as early as day 7, and high titers persisted as late as 6 months. In contrast to immunocompetent littermates, athymic nude mice did not develop antibody after infection. Mice lacking antibody detectable by ELISA were susceptible to lethal MCMV challenge. In a survey of animals from five commercial sources, MCMV antibody was not detected unless mice were experimentally infected. MCMV antibody determination by ELISA is a convenient method, comparable to the indirect immunofluorescence assay in sensitivity and specificity. * Corresponding author. response to MCMV infection and to determine the frequency of preexisting antibody in uninfected mice supplied by commercial sources. MATERIALS AND METHODS Mice. For these experiments, male and female BALB/c AnN, female DBA/2N, and homozygous (nu/nu) and heterozygous (nul+) athymic nude mice were obtained from Charles River Breeding Laboratories, Inc., Kingston, N.Y. C57BLk/1OSCN and BlO.A mice were obtained from Harlan Sprague-Dawley Inc., Madison, Wis. BALB/c heterozygous and homozygous nude mice were obtained from the National Cancer Institute, Frederick, Md. Female BlO.BR and C57BL/1OSNJ (B10) mice were purchased from Jackson Laboratory, Bar Harbor, Maine. In addition, male and female BALB/c AnN and BlO.BR mice were bred in our animal care facility. Animals were maintained in groups of 5 to 10 in isolator units and were fed Laboratory Chow 500 (Ralston Purina, St. Louis, Mo.) and water ad libitum. The colony was monitored for both MCMV infection and other respiratory pathogens. The mice were 6 to 8 weeks of age before use. Virus. The Smith strain of MCMV was originally obtained from M. C. Jordan, University of Minnesota, Minneapolis. The virus was maintained by serial passage in BALB/c mice and was prepared as a 10% (wt/vol) homogenate of salivary gland tissue. The inoculum for sham-infected controls was prepared from the salivary glands of uninfected BALB/c mice. Virus and control stocks were stored at-70°C with 10% dimethyl sulfoxide as a stabilizer. The virus pool for these experiments, which contained 1.6 x 107 PFU of virus per ml, was screened by an antibody generation test (Microbiological Associates, Bethesda, Md.) and was found to be free of other murine pathogens, including pneumonia virus of mice, reovirus type 3, K virus, polyomavirus, Sendai virus, minute virus of mice, murine adenovirus, lymphocytic 600
We compared the effects of acyclovir (ACV) and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) on murine cytomegalovirus (MCMV) replication in lung and salivary gland tissues, the evolution of interstitial pneumonitis in vivo, and MCMV replication in mouse embryo cells in vitro. As measured by plaque reduction, ACV was more active than DHPG in vitro. In vivo, whether administered orally by gastric intubation or in the drinking water, or subcutaneously, DHPG was more effective than ACV in reducing MCMV titers in lung or salivary gland tissues. This was true in both normal and cyclophosphamide-treated mice. Neither drug was able to prevent MCMV interstitial pneumonitis, despite substantial reductions in virus titer, but both drugs reduced the severity of the pneumonitis.Lung infection and interstitial pneumonitis due to cytomegalovirus (CMV) constitute common and often lifethreatening problems for individuals whose immune defenses have been altered by disease or medical therapy (3). The pathogenetic mechanisms leading to CMV lung infection and interstitial pneumonitis are poorly understood. However, the advent of successful antiviral chemotherapy for other herpesvirus infections has prompted a search for therapeutic modalities which might improve the prospects of individuals with pulmonary involvement due to CMV. At present, the available shemotherapeutic agents have poor in vitro antiviral activity against most strains of CMV, and uncontrolled therapeutic trials of agents such as interferon, acyclovir (ACV), and vidarabine against CMV interstitial pneumonitis have been disappointing (4,5,10,11). The search for more effective antiviral agents for the treatment of CMV interstitial pneumonitis is an area of intense interest.We have been studying a model of murine CMV (MCMV) lung infection to better define the roles of host and viral factors in the genesis of MCMV interstitial pneumonitis (8, 9). In BALB/c mice inoculated intranasally with MCMV,
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.